A recently published study demonstrated that tyrosol (10 mg/kg body weight) is capable of improving the three hallmarks of MASH—steatosis, inflammation, and fibrosis—exerting a modulatory activity in both innate and adaptive hepatic immune cell populations in MASH liver, by decreasing inflammatory foci and the accumulation of CD86+ macrophages, restoring the levels of CD4+ CD8− T cells, and increasing those of CD4+ FoxP3+ Treg cells, which are involved in regenerative pathways [71]. Here, CD86 is linked to metabolic dysfunction-associated steatohepatitis.